
Centogene N.V. CNTG
Annual report 2023
added 12-27-2025
Centogene N.V. Operating Expenses 2011-2026 | CNTG
Annual Operating Expenses Centogene N.V.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 58 M | 42.1 M | 30.2 M | 21.3 M | 19.2 M | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 58 M | 19.2 M | 34.2 M |
Operating Expenses of other stocks in the Diagnostics research industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
9.98 M | $ 2.85 | -3.72 % | $ 92.5 K | ||
|
Agilent Technologies
A
|
1.99 B | $ 118.6 | 0.4 % | $ 36.1 B | ||
|
Celcuity
CELC
|
113 M | $ 107.62 | -0.63 % | $ 4.25 B | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 27.55 | -1.59 % | $ 765 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 175.77 | -1.61 % | $ 8.71 B | ||
|
Fulgent Genetics
FLGT
|
181 M | $ 13.82 | -2.68 % | $ 418 M | ||
|
Aspira Women's Health
AWH
|
37.1 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
106 M | $ 15.5 | -1.59 % | $ 2.01 B | ||
|
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
41.3 M | $ 1.12 | -1.78 % | $ 1.42 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 208.28 | -0.95 % | $ 23.1 B | ||
|
Danaher Corporation
DHR
|
6.71 B | $ 204.04 | -0.9 % | $ 145 B | ||
|
Exact Sciences Corporation
EXAS
|
2.47 B | $ 103.38 | 0.02 % | $ 19.5 B | ||
|
Bioventus
BVS
|
217 M | $ 8.8 | 0.34 % | $ 551 M | ||
|
DarioHealth Corp.
DRIO
|
62.2 M | $ 10.3 | -4.19 % | $ 292 M | ||
|
DexCom
DXCM
|
1.89 B | $ 73.0 | -1.06 % | $ 28.5 B | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 108.44 | 0.16 % | $ 8.94 B | ||
|
IDEXX Laboratories
IDXX
|
1.3 B | $ 635.29 | -0.22 % | $ 51.1 B | ||
|
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B | ||
|
Burning Rock Biotech Limited
BNR
|
726 M | $ 24.01 | -4.59 % | $ 254 M | ||
|
Illumina
ILMN
|
3.69 B | $ 129.9 | -2.25 % | $ 20.7 B | ||
|
VolitionRx Limited
VNRX
|
28.3 M | $ 0.2 | -0.74 % | $ 19.2 M | ||
|
CareDx, Inc
CDNA
|
411 M | $ 18.74 | -0.03 % | $ 999 M | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | ||
|
Guardant Health
GH
|
226 M | $ 93.21 | 1.06 % | $ 11.7 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 283.19 | -1.07 % | $ 23.6 B | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 79.15 | 3.74 % | $ 5.34 B | ||
|
IQVIA Holdings
IQV
|
2.94 B | $ 174.33 | 0.03 % | $ 30 B | ||
|
Brainsway Ltd.
BWAY
|
29.2 M | $ 23.2 | -2.09 % | $ 99.4 M | ||
|
Co-Diagnostics
CODX
|
45.3 M | - | - | $ 79.8 M | ||
|
Mettler-Toledo International
MTD
|
1.01 B | $ 1 315.61 | -0.56 % | $ 27.1 B | ||
|
Myriad Genetics
MYGN
|
964 M | $ 5.26 | 4.89 % | $ 487 M | ||
|
NeoGenomics
NEO
|
430 M | $ 9.53 | 0.26 % | $ 1.22 B | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
Natera
NTRA
|
258 M | $ 206.39 | 3.11 % | $ 20.3 B | ||
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
Pacific Biosciences of California
PACB
|
600 M | $ 1.51 | -7.1 % | $ 453 M | ||
|
Neogen Corporation
NEOG
|
1.48 B | $ 10.93 | -1.97 % | $ 2.37 B | ||
|
Precipio
PRPO
|
13.6 M | $ 24.78 | 0.38 % | $ 32.2 M | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B |